BRIEF-Exelixis, Bristol-Myers Squibb initiate phase 3 trial
July 10, 2017 at 09:01 AM EDT
* Exelixis and Bristol-Myers Squibb initiate phase 3 trial of opdivo in combination with cabometyx or opdivo and yervoy in combination with cabometyx, versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma